Table 1 Characteristics of included studies
NO | Author | ESPB group | PVB group | Operation | Analgesic medication | Outcomes | Jada scores | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number | Age (years) | Male (n) | Body mass index (kg/m2) | ASA (I/II) | Methods | Number | Age (years) | Male (n) | Body mass index (kg/m2) | ASA (I/II) | Methods | ||||||
1 | Zhang 2022 | 22 | 54.41 ± 7.61 | 11 | 25.56 ± 3.01 | 7/15 | ESPB with 30 ml of 0.5% ropivacaine hydrochloride | 22 | 54.32 ± 6.56 | 10 | 25.47 ± 2.65 | 9/13 | PVB with 30 ml of 0.5% ropivacaine hydrochloride | Elective thoracoscopic pulmonary lobectomy | 0.05 mg/kg of midazolam, 0.5 μg/kg of sufentanil, 0.6 mg/kg of rocuronium, and 0.3 mg/kg of etomidate Were given sequentially by intravenous infusion | Pain scores at 1–2 h, 4–6 h and 12 h, postoperative analgesic consumption, nausea and vomiting | 4 |
2 | Fu 2022 | 20 | 57.25 ± 11.25 | 14 | 23.4 ± 2.46 | 12/8 | ESPB with 20 ml of 0.5% ropivacaine | 22 | 58.63 ± 6.04 | 8 | 23.79 ± 2.78 | 14/8 | PVB with 20 ml of 0.5% ropivacaine | Video-assisted thoracoscopic surgery | Propofol 2.0 mg/kg, sufentanil 0.4 µg/kg and cis‑atracurium 0.2 mg/kg | Postoperative analgesic consumption, nausea and vomiting | 4 |
3 | Turhan 2021 | 35 | 53.31 ± 9.03 | 19 | 24.38 ± 1.57 | 13/19 | ESPB with 20 mL of 0.5% bupivacaine | 35 | 53.97 ± 7.34 | 16 | 23.78 ± 2.04 | 13/18 | PVB with 20 mL of 0.5% bupivacaine | Thoracoscopic lung surgery | Propofol (2 mg/kg), fentanyl (3 mcg/kg) and rocuronium (0.5 mg/kg) | Pain scores at 1–2 h, 4–6 h and 12 h, postoperative analgesic consumption | 4 |
4 | Zhao 2020 | 33 | 59 ± 5 | 18 | – | 11/21 | ESPB with 15 mL of 0.4% ropivacaine | 33 | 57 ± 6 | 11 | – | 9/24 | PVB with 15 mL of 0.4% ropivacaine | Video-assisted thoracic surgery | Etomidate (0.1 mg/kg), propofol (1 mg/kg), sufentanil (0.3 μg/kg) and cis-atracuronium (0.15 mg/kg) | Postoperative analgesic consumption | 4 |
5 | Çiftçi 2020 | 30 | 47.33 ± 10.21 | 15 | – | 16/14 | ESPB with 20 mL of 0.25% bupivacaine | 30 | 47.53 ± 10.43 | 15 | – | 11/19 | PVB with 20 mL of 0.25% bupivacaine | Video assisted thoracic surgery | Propofol (2–2.5 mg/kg), fentanyl (1–1.5 µg/kg), and rocuronium bromide (0.6 mg/kg) | Postoperative analgesic consumption, nausea and vomiting | 5 |
6 | Chen 2020 | 24 | 51.6 ± 10.4 | 13 | 22.9 ± 2.6 | 9/15 | ESPB with 6.7 ml of 0.375% ropivacaine | 24 | 58.1 ± 7.0 | 15 | 23.5 ± 2.4 | 9/15 | PVB with 7 ml of 0.375% ropivacaine | Elective thoracoscopic partial pulmonary resection surgery | Sufentanil 0.5 μg/kg, propofol 1.5–2.0 mg/kg and rocuronium 0.8 mg/kg | Postoperative analgesic consumption | 5 |
7 | Taketa 2019 | 41 | 70 ± 7 | 23 | 23.6 ± 3.4 | 2/29 | ESPB with 20 mL of 0.2% levobupivacaine | 40 | 67 ± 8 | 25 | 23.4 ± 3.2 | 2/29 | PVB with 20 mL of 0.2% levobupivacaine | Video- assisted thoracic surgery | Fentanyl (50 µg), remifentanil (0.2–0.5 µg/kg/min) and rocuronium (0.6–1 mg/kg) | Pain scores at 1–2 h, 4–6 h and 12 h, nausea and vomiting | 4 |